Malignant peritoneal neoplasm+1
Not yet recruitingMaintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer
Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer
- Disease:Malignant peritoneal neoplasmFallopian tube cancer
- Substances:BevacizumabRaludotatug Deruxtecan
Belgium- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Merck Sharp & Dohme LLC












